Exeplex 25 - Axio Labs

Aromasin, the brand name for Exemestane, was introduced by Pharmacia in 2000 following FDA approval in late 1999. It belongs to the class of steroidal aromatase inhibitors and is known for its irreversible mechanism of action. Designed primarily for hormone-sensitive breast cancer after tamoxifen failure, Exemestane reduces estrogen synthesis by deactivating aromatase. It has become a preferred option among performance users to manage estrogenic issues such as gynecomastia and water retention during anabolic steroid cycles.

Disclaimer: Information provided it this page is for general information only and does not substitute for professional medical advice.

For detailed information about Exeplex 25 by Axio Labs, consult with your doctor or healthcare professional.